One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
XTL Biopharmaceuticals Ltd.
XTLB · NCM · Healthcare · Biotechnology
Current price
$1.96
52-week range
$1.86 - $5.64
Market cap
$4.82M
Balance sheet
Healthy
-197.14x Concerning
Net cash $76.00K. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd. is a company focused on developing medicines for autoimmune diseases, like lupus, in Israel. Their main product is a drug called hCDR1, which they are testing in later-stage trials, and they make money through a deal to develop and sell it. This matters because successfully developing new drugs can lead to significant future sales.
How the company got here
XTL Biopharmaceuticals Ltd. has a history rooted in scientific development, originally known as Xenograft Technologies Ltd. since its incorporation in 1993. The company officially changed its name to XTL Biopharmaceuticals Ltd. in July 1995, signaling a focused shift towards pharmaceutical drug development. Its journey has been centered on acquiring and advancing potential treatments for autoimmune diseases, with a key focus on bringing promising drug candidates through clinical trials.
What it actually does
XTL Biopharmaceuticals is a biopharmaceutical company dedicated to creating new medicines for people suffering from autoimmune diseases. These are conditions where the body's own immune system mistakenly attacks healthy tissues. The company's main goal is to discover, develop, and eventually bring to market drugs that can help manage or treat these challenging conditions, aiming to improve the quality of life for patients.
hCDR1 Drug Development
The core of XTL Biopharmaceuticals' current efforts revolves around its lead drug candidate, hCDR1. This compound is being developed as a potential treatment for autoimmune diseases like systemic lupus erythematosus (lupus) and Sjogren's syndrome. The company has a significant agreement with Yeda Research and Development Company Limited, which allows XTL to research, develop, and commercialize hCDR1 for various medical uses. This drug candidate is currently in the Phase II stage of clinical trials, meaning it is being tested in a larger group of patients to assess its effectiveness and safety.
What management is betting on now
XTL Biopharmaceuticals' strategic focus is squarely on advancing the development of hCDR1 through its clinical trial phases. The company is investing resources to move this drug candidate towards potential approval for treating systemic lupus erythematosus and Sjogren's syndrome. Success in these trials is crucial, as it could pave the way for future commercialization and bring a new therapeutic option to patients with these autoimmune conditions.
Price history
How the share price has moved
—
Loading price history…
Is it cheap or expensive?
Fair value — vs current price $1.96
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $76,000 - more cash than debt. Interest coverage -197.1x.
Net debt
$-76.00K
Interest coverage
-197.14x
Healthy
Worse cushion
Baseline
Better cushion
XTLB
BASELINE
XTL Biopharmaceuticals Ltd.
Total debt $0.00 Interest coverage -197.14x This is the baseline the peer rows are being compared against.
What you should know
The case for and against XTLB
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -29.3% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
—
P/B
—
P/S
—
EV/EBITDA
-3.65x
PEG ratio
2.27x
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-29.3%
ROA
-21.0%
Health
Liquidity and balance-sheet strength
Debt / equity
—
Current ratio
0.40x
Quick ratio
0.18x
Total debt
$0.00
Total cash
$76.00K
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-0.36
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-1.02M
Free CF TTM
$-1.02M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—